VYNE Therapeutics Inc VYNE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor
-
VYNE Therapeutics to Participate in September Investor Conferences
-
VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
-
VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor
-
VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development
Trading Information
- Previous Close Price
- $1.87
- Day Range
- $1.83–1.89
- 52-Week Range
- $1.57–4.48
- Bid/Ask
- $1.80 / $1.89
- Market Cap
- $27.73 Mil
- Volume/Avg
- 18,654 / 42,122
Key Statistics
- Price/Earnings (Normalized)
- 1.02
- Price/Sales
- 115.78
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 10
- Website
- https://www.vynetherapeutics.com
Valuation
|
Metric
|
VYNE
|
|---|---|
Price/Earnings (Normalized) | 1.02 |
Price/Book Value | 0.37 |
Price/Sales | 115.78 |
Price/Cash Flow | — |
Price/Earnings
VYNE
Financial Strength
|
Metric
|
VYNE
|
|---|---|
Quick Ratio | 6.64 |
Current Ratio | 7.13 |
Interest Coverage | — |
Quick Ratio
VYNE
Profitability
|
Metric
|
VYNE
|
|---|---|
Return on Assets (Normalized) | −38.12% |
Return on Equity (Normalized) | −44.27% |
Return on Invested Capital (Normalized) | −44.19% |
Return on Assets
VYNE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Xmpbtqnfr | Clf | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Stypgkts | Rhbhr | $119.6 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Mlbjsjxh | Mygrhfv | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Lppytcc | Phrtv | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Xwcjvmyy | Brw | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Jwpcbrgms | Lzscj | $28.0 Bil | |||
| Moderna Inc
MRNA
| Fpsxbrbc | Dptb | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Sjklxrty | Wpc | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Zwmwvzly | Mkdbjmh | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Ccngllkjf | Rpqqgtn | $12.6 Bil |
United States